CERVARIX amp. 1 vaccine
These diseases include:
precancerous cervical lesions
CERVARIX amp. 1 vaccine
What Cervarix and what it is used?
Cervarix is a vaccine intended to protect females against the diseases caused by infection with human papilloma virus / HPV /
These diseases include:
Precancerous cervical lesions
Types of human papilloma virus contained in the vaccine / HPV types 16 and 18 / are responsible for approximately 70% of cancers of the cervix. Other HPV types can also cause cancer of the cervix. Tservariks s Everything does not protect against HPV types.
When a female is vaccinated with Tservariks, Immune system produces antibodies against HPV types 16 and 18. In clinical trials, it Tserviriks prevent diseases associated with HPV in women aged 15-25 years. Tservariks also stimulates production en antibodies in girls aged 9-14 years.
Tservariks not infectious and therefore can not cause diseases associated with HPV.
Tservariks not used to treat HPV related diseases already present at the time of vaccination.
Tservariks must be used in accordance with official guidelines.
Before you are given Cervarix:
Tservariks shall not apply if the person to be vaccinated:
Is allergic to any of the active substances or to any of the ingredients of Tservariks. Priznatsiet of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.
Has a severe infection with high fever. In this case, it may be necessary to postpone the vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to the doctor.
Take special care with Cervarix:
You should inform your doctor if the person to be vaccinated:
Have problems with bleeding or bruises easily
A disease which reduces her resistance to infections such as HPV infection
Tservariks not protect against diseases caused by infection with NPV type 16 or 18 if they are already infected with human papillomavirus types 16 or 18 at the time of vaccination.
Although vaccination may protect you from cancer of the cervix, it does not replace regular examination of the cervix. You should continue to follow your doctor's advice regarding smear from the cervix / Rahr tests and preventative and protective measures.
Appropriate precautions against exposure to HPV and sexually transmitted diseases should continue as Tservariks not protect against all types of Human Papillomavirus.
Tservariks not protect against other diseases that are caused by the human papilloma virus.
Is currently unknown duration of protection after vaccination. In clinical trials in women aged 15 to 25 years has seen continuous protection up to 6.4 years after the first dose. The need for a booster dose has not been studied.
Taking other medicines:
Tservariks can be given with a combined booster vaccine containing diphtheria, tetanus and pertussis with or without inactivated poliomyelitis or combined hepatitis A and hepatitis B vaccine and hepatitis B vaccine at a separate injection site during the same visit.
The effect of Tservariks may not be optimal if used with medicines that suppress the immune system.
In clinical trials, oral contraceptives reduce the protection obtained by Tservariks.
Please inform the doctor if the person to be vaccinated is taking or has recently taken any other medicines, including medicines obtained without a prescription or has recently received any other vaccine.
Pregnancy and lactation:
Data on the use of Tservariks during pregnancy are not enough. If pregnancy occurs during the course of vaccination, you should consult your doctor.
It is recommended to postpone vaccination until the end of pregnancy.
Ask for advice from your doctor about breastfeeding before you applied Tservariks.
Driving and using machines:
No information on the effect of Tservariks your ability to drive or operate machinery.
How is Cervarix?
The doctor or nurse will give Tservariks as an injection into the muscle of the upper arm.
Tservariks is for women over the age of 9 years. Your doctor or nurse will give you a total of three injections to the following schedule:
First injection: at chosen date
Second injection: 1 month after the first injection
Third injection: 6 months after the first injection.
If necessary, the vaccination schedule can be more flexible. Please consult your doctor for more information.
When Tservariks is given as the first dose is recommended Tservariks be given for the complete vaccination course of three doses.
The vaccine should never be given into a vein.
If you miss a visit next dose Tservariks:
It is important to follow your doctor or nurse regarding return visits. If you forget to visit your doctor at the scheduled time of vaccination, contact your doctor for advice.
If you do not complete the full course of vaccination consists of three injections may not get the best response and protection from the vaccination.
Possible side effects:
Very common - pain or discomfort at the injection site, redness or swelling at the injection site, headache, pain, tenderness or weakness, fatigue
Common - symptoms of gastrointestinal, including nausea, vomiting, diarrhea and abdominal pain, itching, red skin rash, hives, joint pain, fever
Uncommon - infection of the upper respiratory tract, dizziness, other reactions at the injection site induration, tingling or numbness
Adverse events reported since marketing of Tservariks include:
Allergic reactions. They can be recognized by: itchy rash on the hands and feet, swelling of the eyes and face, difficulty breathing or swallowing, a sudden drop in blood pressure and loss of consciousness
These reactions usually occur before leaving the doctor's office. However, if your child is experiencing any of these symptoms should contact a doctor urgently,.
Swollen lymph nodes in the neck, armpit or groin
Fainting sometimes accompanied by shaking or stiffness.
How to store Tservariks?
Keep out of reach of children.
Tservariks Do not use after the expiry date stated on the carton. The expiry date refers to the last day of that month.
Store in refrigerator. Do not freeze. Store in the original package to protect from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
The active substances are:
Human papillomavirus type 16 L1 1 protein 2,3,4 - 20 micrograms
Human papillomavirus type 18 L1 1 protein 2,3,4 - 20 micrograms
Human Papillomavirus = HPV
adjuvant AS04, containing:
-O-desacyl 4 - monophosphoryl lipid A / MPL / 3 to 50 micrograms
adsorbed on aluminum hydroxide, hydrated / Al (OH) 3 / total 0.5 milligrams Al3 +
4L1 protein in the form of neinfiktsiozni virus-like particles produced by recombinant DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from the insect Trichoplusia ni
The other ingredients are sodium chloride, sodium dihydrogen phosphate dihydrate and water for injections.